Literature DB >> 325815

Delayed cutaneous hypersensitivity and human renal allotransplantation.

R T Rolley, S Sterioff, L C Parks, G M Williams.   

Abstract

A group of 154 patients on chronic dialysis has been evaluated by DNCB reactivity. Viewed as a group, these patients exhibit a highly significant decrease in immunologic responsiveness in comparison to normal individuals. However, 19% of patients had an immunologic response to DNCB and 12% an irritant response. This pretransplant DNCB responsiveness correlated significantly with subsequent allograft rejection in 71 renal allotransplant recipients. For example, at 1 year after transplantation graft survival was strikingly different: DNCB- patients, 78%; DNCB+ patients, 29%; and DNCB-IR patients; 20%. Pretransplant recall-antigen testing results in 32 patients did not correlate significantly with subsequent transplant results. Serial posttransplant delayed cutaneous hypersensitivity responses in patients with a positive response to a skin test antigen in the pretransplant period suggest possible usefulness of this technique for detecting rejection in the posttransplant period. DNCB skin testing should be performed in all transplant candidates to evaluate host responsiveness and should aid in future patient management.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 325815

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  3 in total

1.  Delayed-type hypersensitivity and allograft rejection in the mouse: correlation of effector cell phenotype.

Authors:  B E Loveland; I F McKenzie
Journal:  Immunology       Date:  1982-06       Impact factor: 7.397

2.  Blood transfusion suppresses cutaneous cell-mediated immunity.

Authors:  J D Schot; R K Schuurman
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

3.  Cells mediating graft rejection in the mouse. I. Lyt-1 cells mediate skin graft rejection.

Authors:  B E Loveland; P M Hogarth; R Ceredig; I F McKenzie
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.